Rick joined Nouscom in September 2020 from Johnson and Johnson Innovation where he was the Global Oncology Venture and Transaction Lead.

He was Chief Executive Officer of a European clinical stage biotech company, Trino Therapeutics, and previously at Wellcome Trust responsible for maximising financial returns on direct healthcare investments in private and public equities and venture capital funds in their Investment Division.

During this time he was on the board of directors of a number of biotech companies and worked closely with management teams on strategy, financing and exits via M&A and public listings. Prior to this role, Rick was in Business Development where he established and managed a large corporate venture fund, building an extensive external pipeline of preclinical pharmaceutical assets sourced from EU and US academic and biotech labs.

After obtaining a PhD in pharmacology, he started his career in the biotechnology industry at Pharmagene where he helped to establish their therapeutics division and led multi-disciplinary teams in drug development and contract research.